Active
Abcuro
Abcuro’s mission is to develop a new generation of immunomodulatory therapeutics for treating both autoimmunity and cancer. The company uses proprietary analysis of transcriptome data from human disease to identify new approaches to target key compartments of the immune system. Abcuro was launched in 2016 and is based in Newton, Massachusetts.
Abcuro
Abcuro’s mission is to develop a new generation of immunomodulatory therapeutics for treating both autoimmunity and cancer. The company uses proprietary analysis of transcriptome data from human disease to identify new approaches to target key compartments of the immune system. Abcuro was launched in 2016 and is based in Newton, Massachusetts.
CytoImmune Therapeutics
CytoImmune Therapeutics is a clinical-stage cancer immunotherapy company focused on the development and commercialization of novel NK cell therapies that can be infused into patients to eliminate cancer cells. The firm is currently developing proprietary Chimeric Antigen Receptor (CAR)-engineered NK cells (CAR-NK™), which represent an off-the-shelf cell therapy designed to destroy tumor cells by recognizing specific proteins or antigens that are present on the tumor surface.
CytoImmune Therapeutics
CytoImmune Therapeutics is a clinical-stage cancer immunotherapy company focused on the development and commercialization of novel NK cell therapies that can be infused into patients to eliminate cancer cells. The firm is currently developing proprietary Chimeric Antigen Receptor (CAR)-engineered NK cells (CAR-NK™), which represent an off-the-shelf cell therapy designed to destroy tumor cells by recognizing specific proteins or antigens that are present on the tumor surface.
Dynamic Cell Therapies
Dynamic Cell Therapies (DCT) is preclinical stage biotech company developing two platforms: redirectable CAR T-cells and private cytokine signaling systems licensed from the Dana-Farber Cancer Institute.
The company has shown improved efficacy of CAR T-therapies in both in vitro and in vivo multiple myeloma models.
Dynamic Cell Therapies
Dynamic Cell Therapies (DCT) is preclinical stage biotech company developing two platforms: redirectable CAR T-cells and private cytokine signaling systems licensed from the Dana-Farber Cancer Institute.
The company has shown improved efficacy of CAR T-therapies in both in vitro and in vivo multiple myeloma models.
Envisagenics
Envisagenics is an AI-driven biotechnology company founded in 2014 as a spin-out from the Cold Spring Harbor Laboratory that harnesses the therapeutic potential of RNA splicing.
Alternative splicing holds the key to understanding and targeting over 370 diseases, including cancer and neurodegenerative disorders.
Leveraging an extensive map of over 14 million RNA splicing events, Envisagenics’ SpliceCore platform enables the discovery of disease-specific targets, paving the way for the rational design and development of RNA therapeutics and immunotherapies.
Envisagenics currently has several programs focused on various cancer and disease indications, including Multiple Myeloma and other hematologic malignancies and has entered into multiple Pharma research collaborations.
Envisagenics
Envisagenics is an AI-driven biotechnology company founded in 2014 as a spin-out from the Cold Spring Harbor Laboratory that harnesses the therapeutic potential of RNA splicing.
Alternative splicing holds the key to understanding and targeting over 370 diseases, including cancer and neurodegenerative disorders.
Leveraging an extensive map of over 14 million RNA splicing events, Envisagenics’ SpliceCore platform enables the discovery of disease-specific targets, paving the way for the rational design and development of RNA therapeutics and immunotherapies.
Envisagenics currently has several programs focused on various cancer and disease indications, including Multiple Myeloma and other hematologic malignancies and has entered into multiple Pharma research collaborations.
Fortis Therapeutics
Fortis Therapeutics is an immuno-oncology biotech developing a novel antibody-drug conjugate for late-stage multiple myeloma and metastatic castration-resistant prostate cancer. Fortis was founded based on technology exclusively licensed from UCSF and developed in the laboratory of Bin Liu, Ph.D. Fortis is located in COI Pharmaceuticals, Avalon’s Community of Innovation, in San Diego.
Fortis Therapeutics
Fortis Therapeutics is an immuno-oncology biotech developing a novel antibody-drug conjugate for late-stage multiple myeloma and metastatic castration-resistant prostate cancer. Fortis was founded based on technology exclusively licensed from UCSF and developed in the laboratory of Bin Liu, Ph.D. Fortis is located in COI Pharmaceuticals, Avalon’s Community of Innovation, in San Diego.
Indapta Therapeutics
Indapta Therapeutics, Inc. is a biotechnology company focused on developing and commercializing a proprietary, first-in-class, off-the-shelf allogeneic cell therapy to treat multiple types of difficult-to-treat hematologic cancers and solid tumors. Headquartered in San Francisco, Indapta was founded in 2017 by Guy DiPierro along with Ronald Martell and scientists at the University of California, Davis, and Stanford University. The company has developed allogeneic FcRIγ-deficient natural killer cells, known as G-NK cells, and is working to bring this off-the-shelf cell therapy to patients to address the limitations of currently available autologous T-cell therapies.
Indapta Therapeutics
Indapta Therapeutics, Inc. is a biotechnology company focused on developing and commercializing a proprietary, first-in-class, off-the-shelf allogeneic cell therapy to treat multiple types of difficult-to-treat hematologic cancers and solid tumors. Headquartered in San Francisco, Indapta was founded in 2017 by Guy DiPierro along with Ronald Martell and scientists at the University of California, Davis, and Stanford University. The company has developed allogeneic FcRIγ-deficient natural killer cells, known as G-NK cells, and is working to bring this off-the-shelf cell therapy to patients to address the limitations of currently available autologous T-cell therapies.
KAHR
KAHR develops novel dual-targeting fusion protein therapeutics engineered to activate both the innate and the adaptive immune systems simultaneously and localize that response in the tumor microenvironment. KAHR’s lead product candidate, DSP107, is a CD47x41BB targeting compound. DSP107 is being tested in a Phase I/II clinical trial in advanced solid tumors and a Phase 1b clinical trial in blood cancers. KAHR’s preclinical pipeline includes DSP502, a PVRxPD-L1 targeting fusion protein, and DSP216, an HLA-GxCD47 targeting fusion protein.
KAHR
KAHR develops novel dual-targeting fusion protein therapeutics engineered to activate both the innate and the adaptive immune systems simultaneously and localize that response in the tumor microenvironment. KAHR’s lead product candidate, DSP107, is a CD47x41BB targeting compound. DSP107 is being tested in a Phase I/II clinical trial in advanced solid tumors and a Phase 1b clinical trial in blood cancers. KAHR’s preclinical pipeline includes DSP502, a PVRxPD-L1 targeting fusion protein, and DSP216, an HLA-GxCD47 targeting fusion protein.
Luminary Therapeutics
Luminary Therapeutics is a clinical-stage allogeneic cell therapy company focused on combining advanced receptor design with superior cell engineering to overcome antigen escape and T cell dysfunction. Luminary was founded by the team from B-MoGen, which was acquired by Bio-Techne in 2019.
Luminary Therapeutics
Luminary Therapeutics is a clinical-stage allogeneic cell therapy company focused on combining advanced receptor design with superior cell engineering to overcome antigen escape and T cell dysfunction. Luminary was founded by the team from B-MoGen, which was acquired by Bio-Techne in 2019.
Nammi Therapeutics
Nammi Therapeutics, Inc. is an immunotherapy company developing first-in-class products for the treatment of cancer. Nammi’s next-generation masked immunocytokines are tumor antigen-targeting antibodies fused to a cytokine which delivers direct anti-tumor killing capability as well as immune response-initiating activity and inhibits systemic immune activation due to its masking technology.
Nammi Therapeutics
Nammi Therapeutics, Inc. is an immunotherapy company developing first-in-class products for the treatment of cancer. Nammi’s next-generation masked immunocytokines are tumor antigen-targeting antibodies fused to a cytokine which delivers direct anti-tumor killing capability as well as immune response-initiating activity and inhibits systemic immune activation due to its masking technology.
Nectin Therapeutics
Nectin Therapeutics is a biotechnology company aiming to transform the lives of cancer patients by leveraging its unique insights into the nectin pathway to develop the next generation of immune oncology (IO) therapies. The company’s differentiated therapies have the potential to achieve new standards for efficacy and patient response across a number of difficult-to-treat cancers.
Nectin Therapeutics
Nectin Therapeutics is a biotechnology company aiming to transform the lives of cancer patients by leveraging its unique insights into the nectin pathway to develop the next generation of immune oncology (IO) therapies. The company’s differentiated therapies have the potential to achieve new standards for efficacy and patient response across a number of difficult-to-treat cancers.
Opna Bio
Opna Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics. The company’s broad portfolio targets multiple drivers of cancer, including a novel oncology discovery program focused on the fragile-X mental retardation protein (FMRP) and a diversified pipeline of promising oncology assets.
The Opna team has a proven track record of scientific expertise and commercial value creation, having advanced multiple FDA-approved drugs to market.
Opna’s lead clinical compound, OPN-6602, a dual EP300/CBP inhibitor, is currently being studied in a first-in-human Phase 1 clinical trial in multiple myeloma patients.
Opna Bio
Opna Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics. The company’s broad portfolio targets multiple drivers of cancer, including a novel oncology discovery program focused on the fragile-X mental retardation protein (FMRP) and a diversified pipeline of promising oncology assets.
The Opna team has a proven track record of scientific expertise and commercial value creation, having advanced multiple FDA-approved drugs to market.
Opna’s lead clinical compound, OPN-6602, a dual EP300/CBP inhibitor, is currently being studied in a first-in-human Phase 1 clinical trial in multiple myeloma patients.
Reverb Therapeutics
Reverb is a seed-stage oncology company with a highly differentiated platform approach to cytokine therapy. Its Amplifier™ platform uses bispecific antibodies to localize endogenous cytokines to immune cells in the tumor microenvironment (TME) and overcome toxicity issues of exogenously delivered cytokines. Instead of using heavily engineered exogenous cytokines to treat diseases, which present challenges such as systemic toxicity and immunogenicity, Reverb’s antibodies redirect endogenous cytokines already in the body to cells of interest.
Reverb Therapeutics
Reverb is a seed-stage oncology company with a highly differentiated platform approach to cytokine therapy. Its Amplifier™ platform uses bispecific antibodies to localize endogenous cytokines to immune cells in the tumor microenvironment (TME) and overcome toxicity issues of exogenously delivered cytokines. Instead of using heavily engineered exogenous cytokines to treat diseases, which present challenges such as systemic toxicity and immunogenicity, Reverb’s antibodies redirect endogenous cytokines already in the body to cells of interest.
Telo Therapeutics
Telo Therapeutics is developing orally bioavailable next generation inhibitors of nuclear transport, a critical nexus among many cancer cell signaling pathways. The company’s unique chemistry and distinct mechanism of action result in a favorable safety profile and lead to rapid tumor regressions across animal models of multiple cancer types. Telo has generated durable complete responses with just two weeks of dosing in xenografts of both multiple myeloma and glioblastoma.
Telo Therapeutics
Telo Therapeutics is developing orally bioavailable next generation inhibitors of nuclear transport, a critical nexus among many cancer cell signaling pathways. The company’s unique chemistry and distinct mechanism of action result in a favorable safety profile and lead to rapid tumor regressions across animal models of multiple cancer types. Telo has generated durable complete responses with just two weeks of dosing in xenografts of both multiple myeloma and glioblastoma.
TRIO Pharmaceuticals
TRIO Pharmaceuticals, Inc. is a cancer immunotherapeutics company developing a first-in-class antibody drug technology, TRAILBody™.
TRAILBody has the unique distinction of directly eliminating cancer cells without toxins or engaging immune cells and with no activity on normal cells thereby reducing toxicity.
TRIO is developing a specific TRAILBody to treat multiple myeloma in 1st line and relapsed refractory (RR) setting.
TRIO Pharmaceuticals
TRIO Pharmaceuticals, Inc. is a cancer immunotherapeutics company developing a first-in-class antibody drug technology, TRAILBody™.
TRAILBody has the unique distinction of directly eliminating cancer cells without toxins or engaging immune cells and with no activity on normal cells thereby reducing toxicity.
TRIO is developing a specific TRAILBody to treat multiple myeloma in 1st line and relapsed refractory (RR) setting.
Triumvira Immunologics
Triumvira Immunologics is a clinical-stage company developing non-gene edited, first-in-class targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors. The company’s proprietary T cell Antigen Coupler (TAC) technology is a versatile platform that activates natural T cell functions differently from cell therapies such as CAR-T and engineered T cell receptor (TCR) therapies. The lead program, TAC01-HER2, is currently being evaluated in a Phase 1/2 clinical trial for patients with HER2-overexpressing solid tumors (TACTIC-2), including breast, gastric, ovarian, pancreatic, gall bladder and non-small cell lung cancers.
Triumvira Immunologics
Triumvira Immunologics is a clinical-stage company developing non-gene edited, first-in-class targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors. The company’s proprietary T cell Antigen Coupler (TAC) technology is a versatile platform that activates natural T cell functions differently from cell therapies such as CAR-T and engineered T cell receptor (TCR) therapies. The lead program, TAC01-HER2, is currently being evaluated in a Phase 1/2 clinical trial for patients with HER2-overexpressing solid tumors (TACTIC-2), including breast, gastric, ovarian, pancreatic, gall bladder and non-small cell lung cancers.
